Chronic stress impairs GABA A (GABA type A) receptor-mediated inhibition in the hypothalamic paraventricular nucleus (PVN). It is not clear whether GABA B receptor function is also altered. We hypothesize that chronic stress alters GABA B receptor function in PVN corticotrophin-releasing hormone (CRH) neurons to control hypothalamus-pituitary-adrenal axis activity.
Introduction
Persistent, unpredictable and chronic stressful stimuli induce depression-like symptoms in animals and humans and activate the hypothalamus-pituitary-adrenal (HPA) axis (Knoll and Carlezon, 2010) . The corticotrophinreleasing hormone (CRH) neurons in the paraventricular nucleus (PVN) of the hypothalamus play a crucial role as the central driving force in the stress response and may be involved in the development of depression (Holsboer, 2000; Carlson et al., 2007; Culman et al., 2010) . It has been shown that chronic unpredictable stress suppresses GABAergic inhibitory inputs to the PVN neurons that are involved in the regulation of the HPA axis . However, the precise cellular mechanisms of the reduced inhibitory inputs in chronic stress remain unknown.
GABA is the predominant inhibitory neurotransmitter in the central nervous system that activates anion-permeable GABA A receptors and metabotropic GABA B receptors. Activation of ionotropic GABA A receptors induces fast synaptic inhibition, while activation of G protein-coupled GABA B receptors generates slow hyperpolarization through Gα i/o -mediated inhibition of adenylyl cyclase (Couve et al., 2000; Bowery et al., 2002) . GABA B receptors contain a heterodimer of GABA B1 and GABA B2 subunits, both of which are necessary for GABA B receptors to be functionally active (Kaupmann et al., 1997; Malitschek et al., 1999; Calver et al., 2002; Binet et al., 2004) . GABA B receptors are distributed in both presynaptic terminals and postsynaptic soma in the hypothalamus (Misgeld et al., 1995; Lin and Dun, 1998; Margeta-Mitrovic et al., 1999) . Activation of the postsynaptic GABA B receptors opens G protein-activated inwardly rectifying K + channels (GIRKs), which inhibit neuronal activity by generating slow inhibitory postsynaptic currents (IPSCs) (Misgeld et al., 1995; Couve et al., 2000; Bowery et al., 2002) . Presynaptic GABA B receptors function as autoreceptors to inhibit the release of GABA and glutamate by inhibiting N-type Ca 2+ channels and the vesicle fusion process (Yoon et al., 2007) . Previous studies have shown that the GABA B receptor is involved in the pathophysiology of several psychiatric disorders, including anxiety and depression (Pilc and Lloyd, 1984; Pilc and Nowak, 2005) . For instance, GABA B1 and GABA B2 receptor knockout mice exhibit more anxious behaviour and altered depression-like behaviour (Mombereau et al., 2004; Mombereau et al., 2005) . A defect in GABA B -GIRK signalling is involved in the aetiology of schizophrenia and mood disorders (Fatemi et al., 2011) . Foot shock stress impairs GABA B -GIRK function in habenula, and recovery of GABA B -GIRK function ameliorates depression-like behaviour (Lecca et al., 2016) . However, it is not clear whether GABA B receptor function is altered in the PVN in chronic stress. Here, we have tested the hypothesis that chronic unpredictable mild stress (CUMS) suppresses GABA B -GIRK signalling to stimulate PVN-CRH neurons. In this study, we determined whether altered GABA B receptor function contributes to the hyperactivity of PVN-CRH neurons in rats undergoing CUMS.
Methods

Animals
All animal care and experimental protocols conformed to the National Institutes of Health guidelines on the ethical use of animals and were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . This study was carried out with 153 male Sprague Dawley rats (7-10 weeks old). These rats were housed in groups of three rats per cage at a controlled temperature (24-25°C), with food and water ad libitum and a 12 h light/dark cycle except for the light on/off stress procedure. All in vivo and in vitro measurements were obtained by investigators who were blinded to the treatments. All the animals were randomly assigned to different treatments.
The CUMS sequence consists of applying different types of stressors randomly and the CUMS procedure we have used is detailed in Supporting Information Table S1 . The rats were exposed to two of eight different stressors daily (cage rotation, cold isolation, light off, light on, forced swim, restraint stress, isolation housing and food/water deprivation), which varied from day to day, for a period of 11 days according to an established paradigm (Haile et al., 2001; Kosten et al., 2008; Gao et al., 2017) . To avoid the influence of the acute stress effect of the final stressor in the CUMS procedure, we obtained the electrophysiological recordings and measurements of circulating corticosterone levels, 5-10 days after completing the CUMS procedures.
Identification of PVN-CRH neurons
The PVN-CRH neurons were identified as previously described . In brief, an AAV vector was constructed by using the following components: inverted terminal repeat sequence from AAV2, rat Crh promoter, enhanced GFP (eGFP), Woodchuck post-regulatory element 2 and short synthetic polyadenylation. The viral vector was delivered into the rat PVN in vivo through microinjection. Rats were anaesthetized with 2% isoflurane in O 2 , the head was placed in a stereotactic frame, and two 4 mm burr holes was drilled bilaterally around the following coordinates: 1.6-2.0 mm caudal to the bregma and 0.5 mm lateral to the midline to expose the brain. A 0.5 μL Hamilton syringe controlled by a nano-injector was advanced into the PVN according to the stereotaxic coordinates: 1.8-2.1 mm caudal from the bregma, 0.5 mm lateral to the midline and 7.3-7.6 mm deep from the surface of the cortex. The viral vector (50 nL) was delivered into the PVN in a period of 2 min. A period of 3-4 weeks was allowed for Crh promoter-driven eGFP to be expressed in PVN-CRH neurons.
Slice preparation
Hypothalamic slices containing the PVN were prepared from the AAV-injected rats. In brief, rats was decapitated under 2% isoflurane anaesthesia and brains were immediately removed and placed in ice-cold 95% O 2 -5% CO 2 -saturated artificial cerebral spinal fluid (aCSF) that contained (in mM) 124.0 BJP Y Gao et al. NaCl, 3.0 KCl, 1.3 MgSO 4 , 2.4 CaCl 2 , 1.4 NaH 2 PO 4 , 10.0 glucose and 26.0 NaHCO 3 . A tissue block containing the hypothalamus was glued onto the stage of a vibrating microtome (Technical Product International, St. Louis, MO, USA). Coronal hypothalamic slices containing the PVN were cut 300 μm thick, as described previously (Li et al., 2008b; Gao et al., 2017) . The slices were then transferred to a storage chamber, incubated in the aCSF and continuously gassed with 95% O 2 -5% CO 2 at 34°C for at least 1 h before electrophysiological recordings were obtained.
Electrophysiological recordings
Whole-cell voltage clamp recordings were performed in eGFP-tagged PVN neurons in brain slices. A slice was placed in a recording chamber and held to the bottom of the chamber by nylon mesh attached to a U-shaped stainless steel weight. The recording chamber was continuously perfused (3 mL·min À1 ) with aCSF at 34°C maintained by an in-line solution heater and a temperature controller (model TC-324; Warner Instruments LLC, Hamden, CT). The solution was completely exchanged inside the recording chamber iñ 1.5 min. The labelled PVN neurons were identified using an upright microscope (BX51WI; Olympus, Tokyo, Japan) with a combination of epifluorescence illumination and differential interference contrast optics. The recording electrode was pulled from borosilicate capillaries (1.2 mm outer diameter, 0.68 mm inner diameter; World Precision Instruments, Sarasota, FL, USA) using a micropipette puller (P-97; Sutter Instruments, Novato, CA, USA). The resistance of the pipette was 3-7 MΩ when it was filled with internal solution containing (in mM) 110.0 Cs 2 SO 4 , 2.0 MgCl 2 , 0.1 CaCl 2 , 1.1 EGTA, 10.0 HEPES, 2.0 MgATP and 0.3 Na 2 GTP (pH was adjusted to 7.25 with 1 M CsOH; 280-300 mOsmol l À1 ). After a GΩ seal had formed, brief negative pressure was used to obtain the whole-cell configuration. Signals were processed using an Axopatch 700B amplifier (Molecular Devices, Foster City, CA, USA), filtered at 1-2 kHz, digitized at 20 kHz using Digidata 1440 (Molecular Devices) and saved to a computer hard drive (Li et al., 2008b; Gao et al., 2017) . The spontaneous firing activity of eGFP-tagged PVN-CRH neurons was recorded in current clamp configuration. Recording of the firing activity began when the activity had reached a steady state. To determine the postsynaptic GABA B receptor function, we recorded baclofen-induced currents at a holding potential of À60 mV using a pipette solution containing (in mM) 130.0 potassium gluconate, 10.0 NaCl, 1.6 MgCl 2 , 0.1 EGTA, 10 HEPES, 2 MgATP and 0.3 Na 2 GTP. The pH was adjusted to 7.25 with 1 M KOH (280-300 mOsmol l À1 ). To assess the presynaptic GABA B receptor function, we recorded the spontaneous excitatory postsynaptic currents (sEPSCs) at a holding potential of À60 mV in the presence of 20 μM bicuculline. We recorded the spontaneous IPSCs (sIPSCs) at a holding potential of 0 mV in the presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 μM). For possible postsynaptic action mediated by GABA B receptors to be eliminated, a general G protein inhibitor, GDP-β-S (1 mM), was included in the pipette solution in some experiments (Li et al., 2008a) . All drugs were freshly prepared in aCSF before the recording and delivered by syringe pumps at final concentrations.
Quantification of GABA B1 protein
Western blot analysis was used to test GABA B1 expression during changes in the PVN, in CUMS and unstressed rats. Rats were anaesthetized with 2% isoflurane and decapitated. The brains were removed and the hypothalamic slices were sectioned 1.08-2.12 mm caudally to the bregma, and the PVN tissues were micro-punched bilaterally with a slice punch (0.5 mm diameter) following stereotactic coordinates: 0.5 mm lateral to the midline and 1.7-2.5 mm ventral to the surface of the cortex. Total protein was extracted using the BCA method (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. The samples were run using 4-12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Immobilon P; EMD Millipore, Billerica, MA). The immunoblots were probed with a rabbit anti-GABA B1 antibody (1:1000, AGB-001; Alomone Labs, Jerusalem, Israel) and rabbit anti-GAPDH (1:1000, ab37168; Abcam, Cambridge, MA) for 24 h. On the second day, goat-anti-rabbit HRP antibody (1:5000, ab6741; Abcam, Cambridge, MA) was applied to the immunoblots for 2 h at ambient temperature. An ECL kit (Life Sciences, Farmingdale, NY, USA) was used to detect and enhance the protein bands, which were quantified using ImageJ software and normalized by the GAPDH optical density within the same samples.
PVN microinfusion
The PVN microinfusion was performed as described previously . In brief, under anaesthesia with 2% isoflurane, we implanted a bi-barrel guide cannula in the bilateral PVN (26 gauge, 1.0 mm between two barrels, 7.0 mm long from the surface of the skull; Plastic One, Roanoke, VA) . The tips of the guide cannula were 1.0 mm dorsal to the PVN, according to Paxinos and Watson's atlas of the rat brain: 1.8 to 2.0 mm caudal to the bregma and 0.5 mm lateral to the midline. The guide cannula was then affixed to the skull with dental acrylic, and a dummy cannula was inserted into each side of the guide cannula. A dust cap was used to cover the external end of the dummy cannula. After they had recovered from anaesthesia, the rats were returned to their cages and allowed to recover for 5 to 7 days before the microinjection. A bilateral injection cannula with tips protruding 1.0 mm beyond the tip of the guide cannula was placed. Baclofen was dissolved in aCSF and injected bilaterally into the PVN (3.0 nmol in 100 nl for each side). The injection sites in the PVN were then verified at the end of the experiment, as described previously .
Measurement of corticosterone levels
The serum corticosterone levels were measured as described previously . The blood was collected from the orbital sinus of rat under anaesthesia with 2% isoflurane (Parasuraman et al., 2010) . Blood samples were collected from orbital sinus pre-CUMS procedure, pre-PVN infusion and at fixed time points (30, 60, and 90 min) after PVN infusion. An amount of 100 μL blood was collected, to avoid the influence of blood volume loss on hormone secretion. The samples of blood were stored at À80°C before being tested in parallel to minimize the variability in all samples from each experiment. The serum was obtained by centrifuging the blood at high speed in serum collection tubes (4000× g, 5 min). Corticosterone concentrations were measured by an enzyme immunoassay and compared with a standard curve of known corticosterone concentrations, according to the manufacturer's instructions (Enzo Life Sciences, Farmingdale, NY).
Data analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are expressed as the means ± SEM. The estimate of sample size for calculations were performed by using software Minitab (version 17.3.1), and 6-10 neurons per group were required for in vitro electrophysiological recording, and six to eight animals were needed for in vivo experiments to achieve a power of 0.85-0.9. The firing activity was analysed over a period of 3-5 min before, during and after drug administration. The junction potential was corrected off-line on the basis of the composition of the internal and external solution used for the recordings. The GABA B current was presented as the current density, normalized by cell capacitance. The firing rate of the sEPSCs and sIPSCs was analysed off-line using a peak detection programme (Mini-Analysis; Synaptosoft, Leonia, NJ, USA). Events were detected by setting a threshold above the noise level. The effects of drugs on the firing rate, GABA B current and the frequency of sEPSCs and sIPSCs were analysed using ANOVA with Dunn's post hoc test. Two-way ANOVA was used to compare the difference in the baclofen-induced inhibitory effect on of sEPSCs and sIPSCs frequency between control and CUMs rats. P < 0.05 was considered significantly different.
Materials
Baclofen, bicuculline, CNQX, GDP-β-S, AP5 and tertiapin-Q were purchased from Sigma (Abcam, Cambridge, MA, USA). CGP55845 was supplied by abcam, Cambridge, MA.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results PVN-CRH neurons play a pivotal role in the regulation of the HPA axis activity and are activated by stress (Vale et al., 1981) . We identified PVN-CRH neurons in the PVN through the expression of eGFP driven by the rat CRH promoter ( Figure 1A ). The AAV-CRH viral vector (1 × 10 13 titre, 100 nL) was injected into the PVN in four unstressed rats. This viral vector alone did not affect circulating corticosterone levels . The majority of eGFP-tagged (green) neurons were CRH immunopositive (red; Figure 1C ). Using a fluorescent microscope, we were able to view these eGFP-tagged neurons in brain slices and perform electrophysiological recordings using eGFP-tagged neurons from unstressed rats (n = 83 neurons in 50 rats) and CUMS-exposed rats (n = 87 neurons in 51 rats). The basic electrophysiological properties of these neurons did not differ between the neurons from unstressed and CUMS-exposed rats (Table 1) .
Baclofen-induced currents in PVN-CRH neurons in unstressed and CUMS rats
We first determined the postsynaptic current induced by GABA B receptor agonist baclofen in PVN-CRH neurons in unstressed and CUMS rats. Bath application of baclofen (10 μM)
Figure 1 induced outward currents in PVN-CRH neurons in both unstressed and CUMS-exposed rats. These currents were completely eliminated by pre-application of GABA B receptor-specific blocker CGP55845 (2 μM) or by the specific blocker of GIRK channels, tertiapin-Q (1 μM) (Jin and Lu, 1998) . The current density (normalized by cell capacitance) of baclofen-induced currents was significantly smaller in CUMS-exposed rats than in unstressed rats (Figure 2 ). Glutamate application led to GABA B receptor endocytosis through activation of NMDA receptors (Guetg et al., 2010;  Summary data show the density of baclofen -induced currents recorded in PVN-CRH neurons, with or without AP5 treatment, in unstressed and CUMS rats. These data were collected from unstressed rats (vehicle: n = 12 neurons in eight rats, and AP5: n = 12 neurons in seven rats) and CUMS rats (vehicle: n = 12 neurons in seven rats, and AP5: n = 13 neurons in eight rats). Data are means ± SEM. *P < 0.05, significantly different from values in unstressed rats.
Chronic stress and GABA B receptor BJP British Journal of Pharmacology (2017) 174 2929-2940 2933 Kantamneni et al., 2014) , and the glutamate signal was increased in the PVN in chronic stress (Ziegler et al., 2005 ). Thus, we tested the effects of enhanced NMDA receptor activity on GABA B receptor function in the PVN in CUMS rats. The brain slices were incubated in AP5 (50 μM) for 1 h. Baclofen-induced currents were then recorded in aCSF containing AP5 (50 μM) using slices from both unstressed and CUMS-treated rats. AP5 treatment had no significant effect on baclofen-induced currents in 12 PVN-CRH neurons from seven unstressed rats (Figure 2 ). However, AP5 treatment significantly increased baclofen-induced currents in 13 PVN-CRH neurons from eight CUMS-exposed rats (Figure 2A, B) .
CUMS reduced the expression levels of GABA B R1 in the PVN
Since the postsynaptic GABA B receptor function was reduced by CUMS, we determined the levels of GABA B1 protein, using Western immunoblot analysis, in PVN tissue obtained by the micro-punch method. An antibody against GABA B1 was used to detect GABA B receptor protein. CUMS treatment significantly decreased the GABA B1 protein band density in CUMS-exposed rats compared with unstressed rats ( Figure 3A , B). We further determined the role of NMDA receptors in the reduction of GABA B1 expression in the PVN in CUMS rats. The PVN tissues from unstressed rats and CUMS-exposed rats were incubated with 50 μM AP5 for 1 h. Compared with vehicle-treated PVN tissue, AP5 treatment did not change GABA B expression levels in unstressed rats (n = 4) or CUMS-treated rats (n = 4; Figure 3C , D).
CUMS enhanced the inhibitory effect of baclofen on sEPSCs and sIPSCs in PVN-CRH neurons
To assess the function of presynaptic GABA B receptors in controlling glutamatergic synaptic inputs to PVN-CRH neurons in unstressed and CUMS rats, we tested the effect of baclofen on glutamatergic sEPSCs by including 1 mM GDP-β-S in the internal recording solution to block the postsynaptic action of baclofen. The basal frequency of sEPSCs in PVN-CRH neurons was significantly higher in CUMS rats (5.2 ± 0.3 Hz) than in unstressed rats (2.5 ± 0.3 Hz), while the amplitudes of sEPSCs were similar in unstressed and CUMS rats. In both unstressed (n = 12 neurons in six rats) and CUMS rats (n = 14 neurons in seven rats), bath application of 10 μM baclofen significantly reduced the frequency but not the amplitude of sEPSCs in eGFP-tagged PVN-CRH neurons ( Figure 4A ). The extent of the baclofen-induced decrease in the frequency of sEPSCs was significantly greater in CUMS rats (83 ± 4%) than in unstressed rats (53 ± 3%). We next determined the effect of blocking GABA B receptors with CGP55845 on sEPSCs in unstressed rats and CUMS rats. Bath application of 2 μM CGP55845 had no significant effect on the frequency and amplitude of sEPSCs of 14 PVN-CRH neurons in eight unstressed rats. However, in CUMS rats, CGP55845 (2 μM) significantly increased the frequency Figure 3 CUMS treatment decreased expression of GABA B1 (GABA B R1) protein in the PVN. Original gel images (A) and summary data (B) show that GABA B1 protein levels in the PVN were significantly decreased in CUMS rats compared with unstressed rats. Original gel images (C) and summary data (D) show that AP5 treatment (50 μM for 1 h) did not change GABA B1 protein levels in unstressed and CUMS rats. Each group contained four samples, and each sample contained PVN tissues from one rat. The molecular weight is indicated on the right by each band. The GABA B1 protein amounts were quantified by normalizing the density of the protein bands to that of GAPDH in the same samples. The mean values of GABA B1 proteins in unstressed rats were considered to be 1. Data are presented as means ± SEM. *P < 0.05, significantly different from unstressed rats.
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of sEPSCs without affecting the amplitude in 12 PVN-CRH neurons in seven rats ( Figure 4F, G) .
We determined the effect of baclofen on GABAergic sIPSCs in unstressed and CUMS rats. The basal frequency of sIPSCs in CRH neurons was significantly lower in CUMS rats than in unstressed rats (3.5 ± 0.4 Hz, n = 10 neurons in seven unstressed rats, and 2.1 ± 0.3 Hz, n = 12 neurons in eight CUMS rats, P < 0.05), while the amplitude of sIPSCs was similar. Bath application of 10 μM baclofen significantly decreased the frequency of sIPSCs without changing their amplitude in PVN-CRH neurons in unstressed and CUMS rats ( Figure 5 ). The baclofen-induced decrease in the frequency of sIPSCs was significantly greater in CUMS rats (82 ± 6%) than in unstressed rats (53 ± 4%).
Figure 4
CUMS enhanced the inhibitory effect of baclofen (Bac) on sEPSCs in PVN-CRH neurons. (A) Raw traces show sEPSCs recorded at a holding potential of À60 mV during baseline, a bath application of 10 μM baclofen, and washout in PVN-CRH neurons from an unstressed rat and a CUMS rat. (B, C) Cumulative plot analysis of sEPSCs of the same neuron in (A) shows the distribution of the inter-event interval and amplitude during baseline, bath application of baclofen and washout in unstressed (B) and CUMS (C) rats. Summary data show the frequency (D) and amplitude (E) of sEPSCs during baseline, bath application of baclofen and washout in six unstressed rats (n = 12 neurons) and seven CUMS rats (n = 14 neurons). The frequency of sEPSCs in PVN-CRH neurons was significantly higher in CUMS rats than in unstressed rats. Summary data show the frequency (F) and amplitude (G) of sEPSCs during baseline, a bath application of 2 μM CGP55845 (CGP) and washout in 14 PVN-CRH neurons of eight unstressed rats and in 12 PVN-CRH neurons of seven CUMS rats.*P < 0.05, significantly different from baseline values in each group: #P < 0.05, significantly different from baseline values in unstressed group.
CUMS blunted baclofen-induced inhibition of PVN-CRH neurons
We first tested the effect of the GABA B receptor agonist baclofen on the firing activity of eGFP-tagged PVN-CRH neurons. The baseline firing rate was significantly higher in CUMS rats (2.4 ± 0.4 Hz, n = 12 neurons in seven rats) than in unstressed rats (1.1 ± 0.2 Hz, n = 13 neurons in seven rats). In unstressed and CUMS rats, bath application of 1 to 10 μM baclofen led to a dose-dependent reduction in the firing rate in PVN-CRH neurons ( Figure 6A, C) . The magnitude of the decrease and the inhibition extent of the firing activity at different concentrations were significantly greater in unstressed than in CUMS rats ( Figure 6C ).
To determine whether GABA B receptors are tonically activated to control the PVN-CRH neurons, we used the GABA B receptor-specific antagonist CGP55845 at a concentration that is known to completely block GABA B receptors (Kolaj et al., 2004; Li et al., 2008a) . Bath application of CGP55845 had no effect on the firing activity of 10 PVN-CRH neurons in seven unstressed rats. However, CGP55845 significantly increased the firing activity of 12 PVN-CRH neurons in seven CUMS-treated rats ( Figure 6D ).
CUMS impaired the suppression of circulating corticosterone levels induced by activation of GABA B receptors
To determine the physiological roles of GABA B receptors in the PVN in the control of HPA axis activity in CUMS-treated rats, we measured the response of circulating corticosterone levels to the stimulation of GABA B receptors in the PVN. These circulating corticosterone levels were significantly increased after CUMS treatment compared with those in unstressed rats. Bilateral microinjection of baclofen (3.0 nmol in 100 nL on each side) significantly decreased circulating corticosterone levels in six unstressed rats (Figure 7) . Circulating corticosterone levels returned to pre-injection levels within 120 min after baclofen injection. However, in six CUMS rats, baclofen injection induced a non-significant Figure 5 CUMS enhanced inhibitory effect of baclofen (Bac) on sIPSCs in PVN-CRH neurons. (A) Raw traces show sIPSCs recorded at a holding potential of 0 mV during baseline, a bath application of 10 μM baclofen and washout in PVN-CRH neurons from an unstressed and CUMS rat. Cumulative plot analysis of sIPSCs of the same neuron in A showing the distribution of the inter-event interval and amplitude during baseline, bath application of baclofen and washout in unstressed (B) and CUMS (C) rat. Summary data show the frequency (D) and amplitude (E) of sIPSCs during baseline, bath application of baclofen and washout in 10 PVN-CRH neurons from seven unstressed rats and 12 PVN-CRH neurons from eight CUMS rats. The frequency of sIPSCs in PVN-CRH neurons was significantly lower in CUMS rats than in unstressed rats. *P < 0.05, compared with baseline values in each group respectively. #P < 0.05, compared with baseline values in unstressed group.
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decrease in circulating corticosterone levels (Figure 7) . These results indicate that chronic stress causes reduced GABA B receptor function in the control of HPA axis.
Discussion
To our knowledge, this is the first study to determine the plasticity of GABA B receptors in PVN-CRH neurons in response to chronic stress. The PVN-CRH neurons in the PVN are crucial to mediating stress response, and their activity is regulated by excitatory and inhibitory synaptic inputs. GABA is the major inhibitory neurotransmitter in the PVN and its action is mediated by ionotropic GABA A receptors and metabotropic GABA B receptors. We recently found that CUMS caused a depolarizing shift in the GABA reversal potential, which impairs GABAergic inhibition of the PVN-CRH neurons. In the present study, we determined whether chronic stress alters GABA B receptor activity in controlling PVN-CRH neurons and HPA axis activity.
We found that CUMS treatment reduced postsynaptic GABA B receptor currents in PVN-CRH neurons, compared with those in unstressed rats. Previous studies have shown that GABA B receptor function in the cell membrane is controlled by glutamate (Vargas et al., 2008) . For example, sustained glutamate application resulted in the endocytosis of GABA B receptors (Vargas et al., 2008; Maier et al., 2010) , a process that requires the activation of NMDA receptors (Maier et al., 2010) . Thus, we determined the role of NMDA receptors in blunted GABA B receptor function. We found that pretreatment of the brain slices with NMDA receptor antagonist AP5 for a short time led to recovered baclofen-induced currents in PVN-CRH neurons in CUMS rats. Because activation of NMDA receptors induces internalization of GABA B receptors (Guetg et al., 2010; Kantamneni et al., 2014) , it is likely that AP5 treatment blunted the internalization of GABA B receptor to preserve the membrane GABA B receptor in PVN-CRH neurons. These data suggest that enhanced Figure 6 CUMS blunted the inhibitory effect of baclofen (Bac) on PVN-CRH neurons. Raw traces (A) and summary data (B) show that baclofen dose-dependently decreased the firing activity of PVN-CRH neurons. Baclofen induced a smaller inhibition of PVN-CRH neurons (n = 12 neurons) in seven CUMS rats than in unstressed rats (n = 13 neurons in seven rats). (C) Summary data show the percentage inhibition of firing activity of PVN-CRH neurons in both CUMS and unstressed rats. (D) Summary data show that CGP55845 (CGP) (2 μM) had no effect on the firing rate of PVN-CRH neurons (n = 10 neurons) in seven unstressed rats but increased firing activity (n = 12 neurons) in seven CUMS-treated rats. Data are means ± SEM. *P < 0.05, significantly different from control within each group; # P < 0.05, significantly different from unstressed rats.
Figure 7
CUMS blunted baclofen-induced reduction of circulating corticosterone levels. Summary data show circulating corticosterone levels during basal condition, before and after the microinjection of baclofen into the PVN in unstressed (n = 6 rats) and CUMS-treated rats (n = 6 rats). Note that microinjection of baclofen into the PVN significantly decreased corticosterone levels in unstressed rats (n = 6) compared with vehicle injection (n = 6) but induced a smaller decrease in corticosterone levels in CUMS rats (n = 6). *P < 0.05 significantly different from basal values; repeated-measure ANOVA with Dunnett's post hoc test; #P < 0.05, significantly different from values in the unstressed group, unpaired t-test.
NMDA receptor activity in chronic stress is involved in the blunted GABA B receptor function. Furthermore, we found that CUMS treatment significantly reduced GABA B1 protein expression levels in the PVN. This reduced GABA B receptor expression level may also contribute to the blunted GABA B receptor currents in CUMS-treated rats. However, AP5 treatment did not alter GABA B1 protein expression in the PVN in CUMS rats. We cannot rule out the possibility that long-term activation of NMDA receptors in CUMS leads to decreased GABA B receptor expression levels, as the glutamate signal is increased in the PVN in chronic stress (Ziegler et al., 2005) . Thus, the blunted GABA B receptor current in CUMS rats may be due to NMDA-mediated short-term functional impairment and a decrease in the expression levels of GABA B receptors. The PVN region of the hypothalamus contains several types of neurons including PVN-CRH neurons. Thus, CUMS-induced decrease in GABA B1 protein expression in PVN tissue may not represent a decrease in expression levels in PVN-CRH neurons.
Previous studies have shown that chronic stress increases the number of glutamatergic terminals synapsing in opposition to the soma and the number of dendrites of the CRHexpressing neurons (Flak et al., 2009 ) but suppresses GABAergic inputs in the PVN (Verkuyl et al., 2004) . Consistent with these earlier findings, we found that CUMS treatment increased the basal frequency of glutamatergic sEPSCs while reducing the basal frequency of GABAergic sIPSCs in PVN-CRH neurons. The reduction in GABAergic synaptic inputs and increase in glutamatergic synaptic inputs may contribute to the hyperactivity of PVN-CRH neurons in CUMS rats. It is likely that changes in sIPSCs and sEPSCs are caused by altered synaptic transmitter release at the terminal rather than by the activity of glutamatergic and GABAergic neurons, as most of the synaptic circuits may be removed and only local synaptic circuits were largely preserved in our thin-slice preparation. However, it is uncertain whether the altered synaptic release of glutamate and GABA is due to changes in the release probability or the density of presynaptic terminals in the PVN after CUMS treatment.
Because the activation of presynaptic GABA B receptors inhibits GABAergic and glutamatergic synaptic inputs (Misgeld et al., 1995; Li and Pan, 2010) , we assessed presynaptic GABA B receptor function. We observed that baclofen produced a greater inhibitory effect on the frequency of both sEPSCs and sIPSCs in CUMS rats than in unstressed rats. These findings suggest that CUMS enhanced the presynaptic GABA B receptor function in the control of glutamatergic and GABAergic synaptic inputs to the PVN-CRH neurons. Thus, the enhanced reduction of excitatory glutamatergic synaptic inputs may counteract the hyperactivity of PVN-CRH neurons in CUMS, whereas the augmented reduction of inhibitory GABAergic synaptic inputs contributes to it. However, it is not clear whether the GABA B receptor expression levels in the presynaptic terminals that innervate PVN-CRH neurons are also increased in CUMS rats. In addition, we found that blocking GABA B receptors with CGP55845 did not affect the frequency and amplitude of sEPSCs and sIPSCs in unstressed rats, suggesting that GABA B receptors were not tonically activated in controlling glutamate and GABA release in the PVN. However, CGP55845 increased the frequency of sEPSCs but had no effect on sIPSCs in PVN-CRH neurons in CUMS rats. Thus, it is likely that GABA B receptors in the GABAergic terminal are not tonically activated, while GABA B receptors in glutamatergic terminals are tonically activated in the control of glutamate release.
The reasons for the CUMS-induced discrepancy in the alteration in presynaptic and postsynaptic GABA B receptor function are unknown. One possibility is that these receptors are formed by distinct subunit components such as GABA B1a or GABA B1b with GABA B2 (Gassmann and Bettler, 2012) . Also, it is possible that distinct effectors are involved in signalling pathways that are coupled to presynaptic and postsynaptic GABA B receptors (Gassmann and Bettler, 2012) . The activation of presynaptic GABA B receptors inhibits presynaptic Ca 2+ influx and interacts with SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins to limit vesicle fusion and reduce spontaneous neurotransmitter release (Couve et al., 2000; Yoon et al., 2007) . On the other hand, action of postsynaptic GABA B receptor leads to GIRK activation, which reduces neuronal excitability by generating slow IPSC (Couve et al., 2000; Bowery et al., 2002) . It is possible that CUMS treatment causes distinct neuroplasticity in presynaptic terminals and postsynaptic soma. Thus, the mechanisms underlying the plasticity of presynaptic and postsynaptic GABA B receptor function in chronic stress remain to be determined. However, we did not test the effect of blocking the NMDA receptor on presynaptic GABA B receptor function in this study because blocking this receptor may affect presynaptic glutamatergic synaptic inputs. It is difficult to differentiate the role of NMDA receptors or GABA B receptors in the control of presynaptic glutamate release. The role of NMDA receptors in the regulation of presynaptic GABA B receptor function needs to be determined in further studies. Because CUMS impaired postsynaptic GABA B receptor function while enhancing presynaptic GABA B receptor function in the control of neurotransmitter release, we assessed the role of GABA B receptors in the controlling the firing activity of PVN-CRH neurons. CUMS treatment increased this firing activity and blunted the inhibitory effect of baclofen on the firing activity of PVN-CRH neurons. Furthermore, we found that CGP55845 did not significantly change the firing activity of PVN-CRH neurons in unstressed rats, suggesting that the firing activity of the PVN neurons is not tonically affected by GABA B receptors under unstressed conditions. However, blocking GABA B receptors with CGP55845 increased the firing activity of PVN-CRH neurons in CUMStreated rats. Because postsynaptic GABA B receptor activity and GABAergic synaptic inputs to PVN-CRH neurons are already reduced after exposure to CUMS, blockade of the already reduced endogenous GABA B receptor activity had minimal effect on the firing activity of PVN-CRH neurons. Thus, the increase in firing activity by GABA B receptor blockade is likely to be due to an increase in glutamatergic synaptic inputs induced by blocking GABA B receptors in CUMS rats, as blocking GABA B receptors increases frequency of glutamateric EPSCs. Consistent with the blunted GABA B inhibition of PVN-CRH neuron activity, we found that the inhibitory effects of GABA B receptor agonists in the PVN on circulating corticosterone levels was also impaired. In addition to markedly increasing corticosterone levels, CUMS impaired the baclofen-induced inhibition of corticosterone levels.
In summary, the findings of this study indicate that CUMS impaired postsynaptic GABA B receptor function while enhancing presynaptic GABA B receptor function in the control of neurotransmitter release. Such modulation of GABA B receptor function -reduction of postsynaptic receptors and, conversely, enhancement of presynaptic receptors-contribute to the disinhibition of PVN-CRN neurons in CUMS rats. This finding is highly significant because it reveals a novel cellular mechanism that is involved in the control of PVN-CRH neuron activity in chronic stress. Our findings may lead to the development of therapeutic agents that target GABA B receptors for the treatment of neurological disorders, such as depression.
